Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04 2022 - 4:01PM
Business Wire
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the
development of medicines that control the expression of genes,
today announced the grant of a restricted stock unit (RSU) award
for 31,000 shares of Syros common stock to one newly hired employee
in connection with the employee’s commencement of employment with
Syros. These RSUs were granted as a material inducement to
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted on July 29, 2022, vest as to one-quarter
of the shares on March 31, 2023 and as to an additional one quarter
of the shares at the end of each successive year thereafter subject
to the employee’s continued service with Syros, and are subject to
the terms and conditions of a restricted stock unit agreement
covering the award and Syros’ 2022 Inducement Stock Incentive
Plan.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors. Syros also has multiple preclinical and discovery
programs in oncology and monogenic diseases. For more information,
visit www.syros.com and follow us on Twitter (@SyrosPharma) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220804005150/en/
Media Contact Courtney Solberg Syros Pharmaceuticals
917-698-9253 csolberg@syros.com Investor Contact Hannah
Deresiewicz Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Sep 2023 to Sep 2024